Difficulty and doability enacting responsible innovation

Fisher, Elizabeth

doi:10.1080/23299460.2019.1616270

Cited by 4 publications

(2 citation statements)

References 12 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Netherlands Council for Research (NWO) has a dedicated internationally oriented program on responsible innovation. The Research Council of Norway has created the responsible innovation and corporate social responsibility (SAMANSVAR) program, while the NSF has funded the Virtual Institute of Responsible Innovation (VIRI), and the United Kingdom Engineering and Physical Sciences Research Council had a long-standing interest on the subject for at least a decade (see, for a discussion, Owen, 2014;Von Schomberg and Hankins, 2019a;, 2019b.…”

Section: Responsible Innovationmentioning

confidence: 99%

“…The readers in systems sciences, health research, and medical practice can find the diverse conceptual and practical approaches to responsible innovation in the Journal of Responsible Innovation, launched in 2013 (Fisher, 2019b;Guston, 2015), and the International Handbook on Responsible Innovation. A Global Resource, published in 2019 (Von Schomberg and Hankins, 2019b).…”

Section: Responsible Innovationmentioning

confidence: 99%

See 1 more Smart Citation

Digging Deeper into Precision/Personalized Medicine: Cracking the Sugar Code, the Third Alphabet of Life, and Sociomateriality of the Cell

Özdemir

Arğa

Aziz

et al. 2020

OMICS: A Journal of Integrative Biology

Self Cite

View full text Add to dashboard Cite

Precision/personalized medicine is a hot topic in health care. Often presented with the motto ''the right drug, for the right patient, at the right dose, and the right time,'' precision medicine is a theory for rational therapeutics as well as practice to individualize health interventions (e.g., drugs, food, vaccines, medical devices, and exercise programs) using biomarkers. Yet, an alien visitor to planet Earth reading the contemporary textbooks on diagnostics might think precision medicine requires only two biomolecules omnipresent in the literature: nucleic acids (e.g., DNA) and proteins, known as the first and second alphabet of biology, respectively. However, the precision/personalized medicine community has tended to underappreciate the third alphabet of life, the ''sugar code'' (i.e., the information stored in glycans, glycoproteins, and glycolipids). This article brings together experts in precision/personalized medicine science, pharmacoglycomics, emerging technology governance, cultural studies, contemporary art, and responsible innovation to critically comment on the sociomateriality of the three alphabets of life together. First, the current transformation of targeted therapies with personalized glycomedicine and glycan biomarkers is examined. Next, we discuss the reasons as to why unraveling of the sugar code might have lagged behind the DNA and protein codes. While social scientists have historically noted the importance of constructivism (e.g., how people interpret technology and build their values, hopes, and expectations into emerging technologies), life scientists relied on the material properties of technologies in explaining why some innovations emerge rapidly and are more popular than others. The concept of sociomateriality integrates these two explanations by highlighting the inherent entanglement of the social and the material contributions to knowledge and what is presented to us as reality from everyday laboratory life. Hence, we present a hypothesis based on a sociomaterial conceptual lens: because materiality and synthesis of glycans are not directly driven by a template, and thus more complex and open ended than sequencing of a finite length genome, social construction of expectations from unraveling of the sugar code versus the DNA code might have evolved differently, as being future-uncertain versus future-proof, respectively, thus potentially explaining the ''sugar lag'' in precision/personalized medicine diagnostics over the past decades. We conclude by introducing systems scientists, physicians, and biotechnology industry to the concept, practice, and value of responsible innovation, while glycomedicine and other emerging biomarker technologies (e.g., metagenomics and pharmacomicrobiomics) transition to applications in health care, ecology, pharmaceutical/diagnostic industries, agriculture, food, and bioengineering, among others.

show abstract

Section: Responsible Innovationmentioning

confidence: 99%

Section: Responsible Innovationmentioning

confidence: 99%

Digging Deeper into Precision/Personalized Medicine: Cracking the Sugar Code, the Third Alphabet of Life, and Sociomateriality of the Cell

Özdemir

Arğa

Aziz

et al. 2020

OMICS: A Journal of Integrative Biology

Self Cite

View full text Add to dashboard Cite

show abstract

Science, technology, and life politics beyond the market

Thorpe

2020

Journal of Responsible Innovation

View full text Add to dashboard Cite

Arguments in Science & Technology Studies for public participation in decision-making regarding science and technology and for responsible innovation have not adequately addressed the obstacles posed by the economic relations of the market. This paper argues that participation and responsibility are incompatible with the uncontrolled dynamics of the market and with what Gerald Doppelt calls the 'Lockean code' of private ownership of the means of production. Responsible innovation aims, in part, to facilitate the expression of what Anthony Giddens terms 'life politics.' Without challenging the mediation of the relationship between science, technology, and society by the market, arguments for participatory science and technology and responsible innovation remain within the political framework of Giddens' Third Way. This paper makes the case for looking beyond Third Way politics toward socialist democratic planning as the future for participatory and responsible innovation.

show abstract